July 2024 Prescription Drug Affordability Board Meeting

• Date and time: July 22nd, 2024 2:00 pm
• Address:

  Miller Senate Building, William Amoss Room, 4th Floor
  11 Bladen Street
  Annapolis, MD 21401
  United States

Public Comment

The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email [email protected]​ no later than the close of business on Wednesday, July 17, 2024, and provide:

1. Your name
2. Your address
3. The agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.

Written Comment

The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to [email protected]. Please include in the subject line: July 2024 Board Meeting Comments. Please submit any written comments concerning this agenda no later than the close of business on Wednesday, July 17, 2024.

Agenda and Meeting Materials

• ​Agenda (Revised 7/17/2024) - PDF - 89.13 KB
• Minutes​ - PDF - 91.4 KB
• PDAB Regulations COMAR 14.01.02.02​ - PDF - 125.49 KB
• Annual Report: Policies and Options - PDF - 129.22 KB
• UPL Action Plan Update​ - PDF - 126.1 KB
• Cost Review Study Process Next Steps - PDF - 232.78 KB
• July 22, 2024 Meeting Recording
• ​Farxiga Insulins - PDF - 96.89 KB
• Farxiga Proposed Therapeutic Alternatives​ - PDF - 89.35 KB
• Jardiance Insulins - PDF - 96.67 KB
• Jardiance Proposed Therapeutic Alternatives - PDF - 89.25 KB
• Ozempic Insulins​ - PDF - 96.46 KB
• Ozempic Proposed Therapeutic Alternatives - PDF - 88.93 KB
• Trulicity Insulins - PDF - 96.12 KB
• Trulicity Proposed Therapeutic Alternatives - PDF - 88.59 KB

Comments Received for the July 22nd Meeting:

• Written Comment Packet - PDF - 11.06 MB

The following entities provided written comment in the above packet:​

• ​MedChi
• Manva Singla, M.D., F.A.A.P., F.A.A.A.A.I., F.A.C.A.A.A.I., Allergy Asthma Specialists of Maryland​​​
• PhRMA
• Boehringer Ingelheim
• Johnson and Johnson